Amporin Pharmaceuticals

Executive Summary

Amporin Pharmaceuticals, a Swiss biotech founded in 2018, is pioneering a novel class of small molecule therapies targeting amyloid pores—toxic soluble oligomers implicated in protein misfolding diseases such as Alzheimer's, Parkinson's, and ALS. The company's approach aims to protect cellular membranes by blocking, inhibiting, or degrading these pathogenic pores. While still in preclinical stages with no disclosed funding or valuation, Amporin's differentiated mechanism addresses a critical unmet need in neurodegeneration. The pipeline comprises three distinct drug classes, but specific development candidates and timelines remain undisclosed. As a private, early-stage company, Amporin faces significant technical and regulatory risks; however, its innovative strategy and Basel-based R&D expertise position it as a potential emerging player in the neurodegenerative space. Near-term visibility is limited pending public milestones.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead program40% success
• TBDIND/CTA filing for first candidate25% success